secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001171843-22-007235
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q3 core revenue up 30% sequentially to $24.8M; GAAP net loss $29.4M
--------------------------------------------------------------------------------

- Core product/services revenue $24.8M, +30% sequentially; total revenue $25.6M, down from $28.5M YoY.
- GAAP net loss $29.4M vs $13.8M in Q3 2021; non-GAAP net loss $20.8M vs $5.4M.
- Cash, equivalents & short-term investments $185.2M at Sept 30, down from $211.2M at June 30.
- First restructuring phase saves $8M annually; reiterates 65-68% non-GAAP gross margin goal by end of 2023.
- Aiming for positive free cash flow by year-end 2024; launched X9 Real-Time PCR System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000117184322007235/0001171843-22-007235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000117184322007235/f8k_110822.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer